Abemaciclib by Eli Lilly and Co for Primary CNS Lymphoma: Likelihood of Approval
Abemaciclib is under clinical development by Eli Lilly and Co and currently in Phase II for Primary CNS Lymphoma.
Source: pharmaceutical-technology.com
Co Lilly News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Co Lilly. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Co Lilly Today - Breaking & Trending Today
Ramucirumab by Eli Lilly and Co for Metastatic Adenocarcinoma of The Pancreas: Likelihood of Approval
Ramucirumab is under clinical development by Eli Lilly and Co and currently in Phase II for Metastatic Adenocarcinoma of The Pancreas.
Source: pharmaceutical-technology.com
Crenigacestat by Eli Lilly and Co for Chronic Lymphocytic Leukemia (CLL): Likelihood of Approval
Crenigacestatis under clinical development by Eli Lilly and Co and currently in Phase I for Chronic Lymphocytic Leukemia (CLL).
Source: pharmaceutical-technology.com
Global Alzheimer's Disease Therapeutics Market Research Report 2023-2028: Increasing Demand for Biological Therapies with Novel MOAs and Many New Classes of Therapies Looking to Enter the Market
/PRNewswire/ -- The "Alzheimer's Disease Therapeutics Market Forecast - Epidemiology & Pipeline Analysis 2023-2028" report has been added to ResearchAndMarkets....
Source: prnewswire.com
Zai Lab Announces First Quarter 2022 Financial Results and
Company to Host Conference Call and Webcast on May 11, 2022, at 8:00 a.m. ET...
Source: globenewswire.com